Connor, Clark & Lunn Investment Management (CC&L)’s Y-mAbs Therapeutics YMAB Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-11,084
| Closed | -$49.1K | – | 1708 |
|
|
2025
Q1 | $49.1K | Buy |
+11,084
| New | +$49.1K | ﹤0.01% | 1369 |
|
|
2024
Q4 | – | Sell |
-94,225
| Closed | -$1.24M | – | 1676 |
|
|
2024
Q3 | $1.24M | Sell |
94,225
-81,830
| -46% | -$1.08M | 0.01% | 814 |
|
|
2024
Q2 | $2.13M | Sell |
176,055
-26,019
| -13% | -$314K | 0.01% | 638 |
|
|
2024
Q1 | $3.29M | Buy |
202,074
+32,071
| +19% | +$521K | 0.01% | 527 |
|
|
2023
Q4 | $1.16M | Sell |
170,003
-13,945
| -8% | -$95.1K | 0.01% | 822 |
|
|
2023
Q3 | $1M | Sell |
183,948
-1,885
| -1% | -$10.3K | 0.01% | 814 |
|
|
2023
Q2 | $1.26M | Buy |
185,833
+11,719
| +7% | +$79.6K | 0.01% | 730 |
|
|
2023
Q1 | $872K | Buy |
174,114
+3,194
| +2% | +$16K | ﹤0.01% | 745 |
|
|
2022
Q4 | $834K | Buy |
170,920
+127,068
| +290% | +$620K | ﹤0.01% | 750 |
|
|
2022
Q3 | $632K | Buy |
43,852
+7,798
| +22% | +$112K | ﹤0.01% | 764 |
|
|
2022
Q2 | $545K | Buy |
36,054
+9,611
| +36% | +$145K | ﹤0.01% | 755 |
|
|
2022
Q1 | $314K | Buy |
+26,443
| New | +$314K | ﹤0.01% | 865 |
|